DAGFormer: A graph-based domain adaptation approach for single-cell cancer drug response prediction
Open Access
- 19 December 2025
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 21 (12) , e1013832
Abstract
Developing computational methods for single-cell drug response prediction deepens our understanding of tumor heterogeneity and uncovers resistance mechanisms critical to improving cancer therapy. However, current approaches struggle to fully capture intratumoral heterogeneity, as bulk RNA sequencing (bulk RNA-seq) obscures heterogeneity across individual cells, while single-cell RNA sequencing (scRNA-seq) remains constrained by limited throughput and high cost. Current approaches integrating bulk and scRNA-seq data frequently encounter batch effects, impairing robust knowledge transfer. Moreover, most existing methods overlook the role of intercellular interactions, treating cells as isolated entities. To overcome these limitations, we propose DAGFormer, a Graph-based Domain Adaptation framework that integrates bulk and scRNA-seq data for predicting single-cell drug responses. DAGFormer constructs cellular neighbor graphs using diverse topological strategies and employs Graph Domain Adaptation (GDA) to bridge graph-level distribution gaps between bulk and single-cell RNA-seq data. A dual-domain decoder further disentangles shared and modality-specific representations, preserving both general and unique biological signals. Benchmarking DAGFormer on ten independent scRNA-seq datasets demonstrated its superior performance compared to existing methods, underscoring its effectiveness and robustness in cancer drug response prediction.Keywords
Funding Information
- National Key R&D Program of China (2020YFA0908700)
- National Nature Science Foundation of China (62176164)
- National Nature Science Foundation of China (62522316)
- National Nature Science Foundation of China (62472353)
- Natural Science Foundation of Guangdong Province (2023A1515010992)
- Guangdong Basic and Applied Basic Research Foundation (2024A1515011984)
- Science and Technology Innovation Committee Foundation of Shenzhen City (JCYJ20220531101217039)
This publication has 42 references indexed in Scilit:
- EZH2: The roles in targeted therapy and mechanisms of resistance in breast cancerBiomedicine & Pharmacotherapy, 2024
- A review of computational methods for predicting cancer drug response at the single-cell level through integration with bulk RNAseq dataCurrent Opinion in Structural Biology, 2023
- Addressing Modern Diagnostic Pathology for Patient-Derived Soft Tissue Sarcosphere Models in the Era of Functional Precision OncologyLaboratory Investigation, 2023
- AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer CellsJournal of Thoracic Oncology, 2020
- Intratumor Heterogeneity: The Rosetta Stone of Therapy ResistanceCancer Cell, 2020
- Extracellular vesicles and anti-cancer drug resistanceBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2018
- Three‐dimensional cell culture models for anticancer drug screening: Worth the effort?Journal of Cellular Physiology, 2017
- A Landscape of Pharmacogenomic Interactions in CancerCell, 2016
- Deciphering intratumor heterogeneity using cancer genome analysisHuman Genetics, 2016
- The emergence of macrocyclic lactone resistance in the canine heartworm,Dirofilaria immitis.Parasitology, 2015